NASDAQ: BDTX - Black Diamond Therapeutics, Inc.

Yield per half year: -63.27%
Dividend yield: 0.00%
Sector: Healthcare

Company Analysis Black Diamond Therapeutics, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (1.62 $) is less than fair price (3.6 $)
  • Current debt level 15.31% is below 100% and has decreased over 5 years from 126.73%.

Disadvantages

  • Dividends (0%) are below the sector average (0.5467%).
  • The stock's return over the last year (-66.94%) is lower than the sector average (-28.78%).
  • The company's current efficiency (ROE=-69.67%) is lower than the sector average (ROE=9.01%)

Similar companies

Illumina

Incyte

ImmunoGen

DENTSPLY SIRONA

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Black Diamond Therapeutics, Inc. Healthcare Index
7 days -5.8% -21.6% -2%
90 days -26% -28.5% -12.1%
1 year -66.9% -28.8% 6.4%

BDTX vs Sector: Black Diamond Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -38.15% over the past year.

BDTX vs Market: Black Diamond Therapeutics, Inc. has significantly underperformed the market by -73.31% over the past year.

Stable price: BDTX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: BDTX with weekly volatility of -1.29% over the past year.

3. Summary of the report

3.1. General

P/E: 24.01
P/S: 0

3.2. Revenue

EPS -1.27
ROE -69.67%
ROA -49.55%
ROIC -49.83%
Ebitda margin 0%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (1.62 $) is lower than the fair price (3.6 $).

Price significantly below the fair price: The current price (1.62 $) is 122.2% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (24.01) is lower than that of the sector as a whole (57.09).

P/E vs Market: The company's P/E (24.01) is lower than that of the market as a whole (48.45).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.41) is lower than that of the sector as a whole (4.61).

P/BV vs Market: The company's P/BV (1.41) is lower than that of the market as a whole (3.38).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (33.5).

P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (10.23).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-1.27) is higher than that of the sector as a whole (-19.46).

EV/Ebitda vs Market: The company's EV/Ebitda (-1.27) is lower than that of the market as a whole (15.44).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 0.7988% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0.7988%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (38.84%).

5.4. ROE

ROE vs Sector: The company's ROE (-69.67%) is lower than that of the sector as a whole (9.01%).

ROE vs Market: The company's ROE (-69.67%) is lower than that of the market as a whole (8.97%).

5.5. ROA

ROA vs Sector: The company's ROA (-49.55%) is lower than that of the sector as a whole (0.0151%).

ROA vs Market: The company's ROA (-49.55%) is lower than that of the market as a whole (6.3%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-49.83%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-49.83%) is lower than that of the market as a whole (10.96%).

6. Finance

6.1. Assets and debt

Debt level: (15.31%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 126.73% to 15.31%.

Excess of debt: The debt is not covered by net income, percentage -26.96%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5467%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Selling More insider purchases by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Black Diamond Therapeutics, Inc.

9.3. Comments